PTC Therapeutics Increases Full Year 2026 Financial Guidance
PTC Therapeutics raised its full-year 2026 revenue and product revenue guidance following its third-quarter earnings report.
Stocks · News reference
Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Raises Price Target to $137
Cantor Fitzgerald analyst Kristen Kluska maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $130 to $137.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
PTC Therapeutics Reports Third-Quarter 2026 Financial Results
PTC Therapeutics announced its third-quarter 2026 financial results, reporting revenue of $357.8 million and a net loss of $51.7 million.
8-K filing — PTC THERAPEUTICS, INC. (PTCT)
Filed: 2026-10-29 AccNo: 0001104659-26-120200 Size: 5 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
RBC Capital Maintains Sector Perform on PTC Therapeutics, Lowers Price Target to $75
RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:PTCT) with a Sector Perform and lowers the price target from $85 to $75.